International Clinical Trial: Phase 2 Double-blind Placebo-controlled Multicenter Cross-over Study with Titration Period to Evaluate the Efficacy and Safety of IRX211a for the Treatment of Breakthrough Cancer Pain in Opioid Tolerant Patients

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (ACTRN12625000898459) titled 'Phase 2 Double-blind Placebo-controlled Multicenter Cross-over Study with Titration Period to Evaluate the Efficacy and Safety of IRX211a for the Treatment of Breakthrough Cancer Pain in Opioid Tolerant Patients' on Aug. 18.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Randomised controlled trial

Primary Sponsor: InhaleRx Ltd.

Condition: Breakthrough Cancer Pain Breakthrough Cancer Pain Anaesthesiology - Pain management Cancer - Any cancer

Intervention: This multicentre phase 2 study investigates the use of IRX211a (dronabinol), an inhaled cannabinoid formulation administered ...